EPCAM and breast cancer: Nanou et al. [54] recently reported a similar prognostic power for EpCAM+ cytokeratin (CK) circulating tumor cells (CTCs) and tumor-derived EVs (tdEVs), as well as EpCAM+ CK+ CTCs and tdEVs in BC, by including anti-HER2 in the CellSearch assay.